MEMBER PREVIEW
All 16 treated patients remained disease-free in a small Phase 1 study, but the trial was not large enough to establish statistical significance.
IMPORTANT INTELLIGENCE · ₹99 / ₹199
THE INVESTOR ANALYSIS CONTINUES BEHIND THE GRID.
Unlock the full analysis, investor takeaways, risk map, watch points and source record with IMG Premium. The ₹199 plan also includes Grid Minds, Investor Lens podcasts, In Brief and the daily morning and evening PDFs.
Continue to membership in your browser ↗Informational research only. No personalised recommendation or assured-return claim.